Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 195739, 7 pages
http://dx.doi.org/10.1155/2014/195739
Research Article

The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate

1European Genomic Institute for Diabetes (EGID) FR 3508, University of Lille, CNRS UMR 8199, and Faculty of Medicine West, 1 Place de Verdun, 59045 Lille, France
2Department of Endocrine Surgery, Lille University Hospital, INSERM UMR 859, University of Lille, EGID FR 3508, Biotherapies for Diabetes, Lille, France

Received 28 August 2014; Revised 26 November 2014; Accepted 7 December 2014; Published 31 December 2014

Academic Editor: Kazuya Yamagata

Copyright © 2014 Valérie Plaisance et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bonnefond, P. Froguel, and M. Vaxillaire, “The emerging genetics of type 2 diabetes,” Trends in Molecular Medicine, vol. 16, no. 9, pp. 407–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Prentki and C. J. Nolan, “Islet β cell failure in type 2 diabetes,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1802–1812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Y. Donath, M. Böni-Schnetzler, H. Ellingsgaard, P. A. Halban, and J. A. Ehses, “Cytokine production by islets in health and diabetes: Cellular origin, regulation and function,” Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 261–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Lundh, D. P. Christensen, M. Damgaard Nielsen et al., “Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children,” Diabetologia, vol. 55, no. 9, pp. 2421–2431, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. H.-C. Chou, E. B. Holson, F. F. Wagner et al., “Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis,” Chemistry & Biology, vol. 19, no. 6, pp. 669–673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Knipstein and L. Gore, “Entinostat for treatment of solid tumors and hematologic malignancies,” Expert Opinion on Investigational Drugs, vol. 20, no. 10, pp. 1455–1467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Lin, K. Song, N. Lim et al., “Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score-the CoLaus Study,” Diabetologia, vol. 52, no. 4, pp. 600–608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Paolisso, P. A. Tataranni, J. E. Foley, C. Bogardus, B. V. Howard, and E. Ravussin, “A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM,” Diabetologia, vol. 38, no. 10, pp. 1213–1217, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Eguchi, I. Manabe, Y. Oishi-Tanaka et al., “Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation,” Cell Metabolism, vol. 15, no. 4, pp. 518–533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. Meier, T. G. K. Breuer, R. C. Bonadonna et al., “Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans,” Diabetologia, vol. 55, no. 5, pp. 1346–1354, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses, “Islet inflammation in type 2 diabetes: from metabolic stress to therapy,” Diabetes Care, vol. 31, supplement 2, pp. S161–S164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dubois, J. Kerr-Conte, V. Gmyr et al., “Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration,” Diabetologia, vol. 47, no. 3, pp. 463–469, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. K. Hagman, L. B. Hays, S. D. Parazzoli, and V. Poitout, “Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans,” Journal of Biological Chemistry, vol. 280, no. 37, pp. 32413–32418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Poitout and R. P. Robertson, “Minireview: secondary β-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity,” Endocrinology, vol. 143, no. 2, pp. 339–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Plaisance, V. Perret, D. Favre et al., “Role of the transcriptional factor C/EBPβ in free fatty acid-elicited β-cell failure,” Molecular and Cellular Endocrinology, vol. 305, no. 1-2, pp. 47–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Kashyap, R. Belfort, A. Gastaldelli et al., “A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2461–2474, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. L. Watson, K. Macrae, A. E. Marley, and H. S. Hundal, “Chronic effects of palmitate overload on nutrient-induced insulin secretion and autocrine signalling in pancreatic MIN6 beta cells,” PLoS ONE, vol. 6, no. 10, Article ID e25975, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Cnop, L. Ladrière, M. Igoillo-Esteve, R. F. Moura, and D. A. Cunha, “Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction,” Diabetes, Obesity and Metabolism, vol. 12, supplement 2, pp. 76–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Akerfeldt, J. Howes, J. Y. Chan et al., “Cytokine-Induced β-cell death is independent of endoplasmic reticulum stress signaling,” Diabetes, vol. 57, no. 11, pp. 3034–3044, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Kharroubi, L. Ladrière, A. K. Cardozo, Z. Dogusan, M. Cnop, and D. L. Eizirik, “Free fatty acids and cytokines induce pancreatic β-cell apoptosis by different mechanisms: role of nuclear factor-κB and endoplasmic reticulum stress,” Endocrinology, vol. 145, no. 11, pp. 5087–5096, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. D. R. Laybutt, A. M. Preston, M. C. Åkerfeldt et al., “Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes,” Diabetologia, vol. 50, no. 4, pp. 752–763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. L. Eizirik, A. K. Cardozo, and M. Cnop, “The role for endoplasmic reticulum stress in diabetes mellitus,” Endocrine Reviews, vol. 29, no. 1, pp. 42–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Shi, S. I. Taylor, S.-L. Tan, and N. Sonenberg, “When translation meets metabolism: multiple links to diabetes,” Endocrine Reviews, vol. 24, no. 1, pp. 91–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. H.-Y. Jiang, S. A. Wek, B. C. McGrath et al., “Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response,” Molecular and Cellular Biology, vol. 24, no. 3, pp. 1365–1377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. G. Hartman, D. Lu, M.-L. Kim et al., “Role for activating transcription factor 3 in stress-induced β-cell apoptosis,” Molecular and Cellular Biology, vol. 24, no. 13, pp. 5721–5732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Marchetti, M. Bugliani, R. Lupi et al., “The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients,” Diabetologia, vol. 50, no. 12, pp. 2486–2494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. J. Zmuda, L. Qi, M. X. Zhu, R. G. Mirmira, M. R. Montminy, and T. Hai, “The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic β-cell dysfunction,” Molecular Endocrinology, vol. 24, no. 7, pp. 1423–1433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Oyadomari, A. Koizumi, K. Takeda et al., “Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes,” Journal of Clinical Investigation, vol. 109, no. 4, pp. 525–532, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. A. K. Busch, D. Cordery, G. S. Denyer, and T. J. Biden, “Expression profiling of palmitate- and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic β-cell function,” Diabetes, vol. 51, no. 4, pp. 977–987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Lilla, G. Webb, K. Rickenbach et al., “Differential gene expression in well-regulated and dysregulated pancreatic β-cell (MIN6) sublines,” Endocrinology, vol. 144, no. 4, pp. 1368–1379, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ferdaoussi, S. Abdelli, J.-Y. Yang et al., “Exendin-4 protects β-cells from interleukin-1β-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway,” Diabetes, vol. 57, no. 5, pp. 1205–1215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M.-C. Vantyghem, J. Kerr-Conte, L. Arnalsteen et al., “Primary graft function, metabolic control, and graft survival after islet transplantation,” Diabetes Care, vol. 32, no. 8, pp. 1473–1478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Favre, E. Le Gouill, D. Fahmi et al., “Impaired expression of the inducible cAMP early repressor accounts for sustained adipose CREB activity in obesity,” Diabetes, vol. 60, no. 12, pp. 3169–3174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Ezanno, V. Pawlowski, S. Abdelli et al., “JNK3 is required for the cytoprotective effect of exendin 4,” Journal of Diabetes Research, vol. 2014, Article ID 814854, 5 pages, 2014. View at Publisher · View at Google Scholar
  37. D. A. Cunha, P. Hekerman, L. Ladrière et al., “Initiation and execution of lipotoxic ER stress in pancreatic β-cells,” Journal of Cell Science, vol. 121, no. 14, pp. 2308–2318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Sargsyan and P. Bergsten, “Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells,” Lipids in Health and Disease, vol. 10, article 115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Malmgren, P. Spégel, A. P. H. Danielsson et al., “Coordinate changes in histone modifications, mRNA levels, and metabolite profiles in clonal INS-1 832/13 β-cells accompany functional adaptations to lipotoxicity,” The Journal of Biological Chemistry, vol. 288, no. 17, pp. 11973–11987, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. R. G. Fred, C. H. Bang-Berthelsen, T. Mandrup-Poulsen, L. G. Grunnet, and N. Welsh, “High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression,” PLoS ONE, vol. 5, no. 5, Article ID e10843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Kato, H. Shimano, T. Yamamoto et al., “Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets,” Diabetes, vol. 57, no. 9, pp. 2382–2392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Iizuka, H. Nakajima, M. Namba et al., “Metabolic consequence of long-term exposure of pancreatic β cells to free fatty acid with special reference to glucose insensitivity,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1586, no. 1, pp. 23–31, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Hu, E. Dul, C.-M. Sung et al., “Identification of novel isoform-selective inhibitors within class I histone deacetylases,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 2, pp. 720–728, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Karagianni and J. Wong, “HDAC3: taking the SMRT-N-CoRrect road to repression,” Oncogene, vol. 26, no. 37, pp. 5439–5449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. D. P. Christensen, M. Dahllöf, M. Lundh et al., “Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus,” Molecular Medicine, vol. 17, no. 5-6, pp. 378–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. Z. Gao, J. Yin, J. Zhang et al., “Butyrate improves insulin sensitivity and increases energy expenditure in mice,” Diabetes, vol. 58, no. 7, pp. 1509–1517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Galmozzi, N. Mitro, A. Ferrari et al., “Inhibition of class i histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue,” Diabetes, vol. 62, no. 3, pp. 732–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Larsen, M. Tonnesen, S. G. Ronn et al., “Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells,” Diabetologia, vol. 50, no. 4, pp. 779–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. B. C. Meier and B. K. Wagner, “Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics,” Epigenomics, vol. 6, no. 2, pp. 209–214, 2014. View at Publisher · View at Google Scholar · View at Scopus